Discover
INKT
MiNK Therapeutics, Inc.
11.46
2 x 8.15
2 x 14.46
bid
ask
-
0.23
1.97%
2 @ 04:00 PM
11.48 +0.02 (0.18%)
| Ytd | 2.78% | |
| 1y | 56.13% |
11.16
day range
11.73
6.80
52 week range
76.00
| Open | 11.51 | Prev Close | 11.69 | Low | 11.16 | High | 11.73 | Mkt Cap | 57.09M |
| Vol | 12.20K | Avg Vol | 41.01K | EPS | -2.80 | P/E | N/A | Forward P/E | -1.17 |
| Beta | 0.05 | Short Ratio | 1.10 | Inst. Own | 2.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 11.53 | 200-d Avg | 12.07 | 1yr Est | 6.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.08 | -0.05 | 0.03 | 37.50% |
| 2024-08-13 | 2024-06 | -0.1 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.1 | -0.07 | 0.03 | 30.00% |
| 2024-05-14 | 2024-03 | -0.16 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.16 | -0.11 | 0.05 | 31.25% |
| 2024-03-21 | 2023-12 | -0.15 | -0.16 | -0.01 | -6.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-15 | Baird | Upgrade | Outperform | Outperform |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-10-15 | AGENUS, INC. | Beneficial Owner of more than 10% of a Class of Security | 21.77M | Purchase |
| 2023-05-04 | ARMEN GARO H. | Director | 1.87M | Sale |
| 2023-08-31 | BALDONI JOHN | Director | 41.19K | Stock Award(Grant) |
| 2024-11-28 | BEHNER PETER | Director | 133.63K | Stock Award(Grant) |
| 2023-09-26 | BUELL JENNIFER | Chief Executive Officer | 1.08M | Conversion of Exercise of derivative security |
| 2024-11-28 | CORVESE BRIAN J | Director | 426.28K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 234.18K | 115.03K | 0.59% |
| 2024-09-29 | Longbow Finance Sa | 166.67K | 81.87K | 0.42% |
| 2024-09-29 | Renaissance Technologies, LLC | 106.69K | 52.40K | 0.27% |
| 2024-09-29 | Geode Capital Management, LLC | 97.98K | 48.13K | 0.25% |
| 2024-09-29 | Blackrock Inc. | 88.13K | 43.29K | 0.22% |
| 2024-09-29 | HighTower Advisors, LLC | 51.73K | 25.41K | 0.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 148.23K | 72.81K | 0.37% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 85.95K | 42.22K | 0.22% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 56.82K | 27.91K | 0.14% |
| 2024-10-30 | iShares Micro Cap ETF | 22.49K | 11.05K | 0.06% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 19.03K | 9.35K | 0.05% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 11.66K | 5.73K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2025-01-28 |